<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335956</url>
  </required_header>
  <id_info>
    <org_study_id>CORT125281-600</org_study_id>
    <nct_id>NCT03335956</nct_id>
  </id_info>
  <brief_title>CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAD and MAD of CORT125281 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corcept Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corcept Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This initial Phase I study will evaluate the dose-related safety and tolerability
      pharmacokinetics (PK) of CORT125281, and CORT125324 (active metabolite), and pharmacodynamics
      (PD) after single and multiple ascending oral doses of CORT125281 in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Separate single-and multiple-ascending dose (SAD and MAD) parts will be conducted. Throughout
      each part of the study, safety, pharmacological (PD) and PK effects will be assessed. Safety
      and tolerability will be assessed using adverse event (AE) monitoring, measurement of vital
      signs, recording 12-lead electrocardiogram (ECG), physical examination and clinical
      laboratory safety tests. Blood samples will be collected at intervals for assay of plasma
      concentration of CORT125281 and CORT125324.

      The SAD part of the study is double-blind, randomized and placebo-controlled with respect to
      CORT125281. Two cohorts, each of 9 subjects, will receive three sequential single doses of
      the investigational medicinal product (IMP), either CORT125281 at the assigned dose level or
      placebo, in a partial within-subject crossover manner. The starting dose is CORT125281, 40
      mg; the rules for determining later doses are detailed within the protocol. The PD effects of
      CORT125281 will be examined by testing its ability to ameliorate the pharmacological effects
      of a concomitantly administered dose of prednisone.

      The MAD part of the study will be double-blind, randomized, placebo-controlled and
      parallel-group with respect to CORT125281. Up to four cohorts of 8 subjects, randomized so
      that 6 receive CORT125281 and 2 receive placebo, will participate in the study, so that up to
      four dose levels of CORT125281 are studied in total. An exploratory assessment will be made
      of the effect of repeated doses of CORT125281 on exposure to pioglitazone, probe substrate
      for CYP2C8. Each subject will be admitted on Day−1 for baseline assessments. On Day1,
      subjects will receive a single oral dose of pioglitazone, 15mg. From Day3 to Day16 (14 days),
      subjects will be dosed daily with IMP (CORT125281 at the selected dose or placebo). On Day13,
      subjects will receive a second dose of pioglitazone, 15 mg.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>SAD Cohorts Day 1 to Day 14; MAD Cohorts Day 1 to Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCtau Pharmacokinetic (PK) parameter</measure>
    <time_frame>MAD Cohorts Day 3 to 19</time_frame>
    <description>Area under the curve over a dose-interval (AUCtau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-tz PK parameter</measure>
    <time_frame>CORT125281/CORT125324 - SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19; Pioglitizone - MAD Cohort Day 1 to 15</time_frame>
    <description>Area under the curve from the time of dosing until the last quantifiable concentration (AUC 0-tz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC 0-infinity PK parameter</measure>
    <time_frame>CORT125281/CORT125324 - SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19; Pioglitizone - MAD Cohort Day 1 to 15</time_frame>
    <description>Area under the curve from the time of dosing extrapolated to infinity (AUC 0-infinity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax PK parameter</measure>
    <time_frame>CORT125281/CORT125324 - SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19; Pioglitizone - MAD Cohort Day 1 to 15</time_frame>
    <description>Maximum concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin PK parameter</measure>
    <time_frame>MAD Cohorts Day 3 to 19</time_frame>
    <description>Minimum concentration within a dose interval (Cmin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax PK parameter</measure>
    <time_frame>SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19</time_frame>
    <description>Time to maximum concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tlag PK parameter</measure>
    <time_frame>SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19</time_frame>
    <description>Latest time after dosing before the first quantifiable concentration (tlag)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent terminal rate constant PK parameter</measure>
    <time_frame>SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 PK parameter</measure>
    <time_frame>SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19</time_frame>
    <description>Apparent terminal elimination half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT PK parameter</measure>
    <time_frame>SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19</time_frame>
    <description>Mean residence time (MRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F PK parameter</measure>
    <time_frame>SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19</time_frame>
    <description>Apparent oral volume of distribution during the terminal elimination phase (Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F PK parameter</measure>
    <time_frame>SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19</time_frame>
    <description>Apparent oral clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed accumulation ratio PK parameter</measure>
    <time_frame>MAD Cohorts Day 3 to 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4β-OH cholesterol PK parameter</measure>
    <time_frame>MAD Cohorts Day 1 to Day 17</time_frame>
    <description>4β-Hydroxycholesterol (4β-OH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) Peripheral blood neutrophil, eosinophil and lymphocyte counts</measure>
    <time_frame>SAD Cohorts pre-dose through 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Serum osteocalcin</measure>
    <time_frame>SAD Cohorts pre-dose through 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Pre- and postprandial blood glucose</measure>
    <time_frame>SAD Cohorts Day 1, pre-dose to 6 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Cytokines</measure>
    <time_frame>SAD Cohorts Day 1, pre-dose to 24 hours post dose; MAD Cohorts Day 3 to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD T cell profiling by flow cytometry</measure>
    <time_frame>SAD Cohorts Day 1, pre-dose to 24 hours post dose; MAD Cohorts Day 3 to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Gene expression for glucocorticoid-modulated genes</measure>
    <time_frame>SAD Cohorts Day 1, pre-dose to 4 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Cortisol</measure>
    <time_frame>MAD Cohorts pre-dose to Day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD ACTH</measure>
    <time_frame>MAD Cohorts pre-dose to Day 16</time_frame>
    <description>Adrenocorticotropic hormone (ACTH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD DHEA S</measure>
    <time_frame>MAD Cohorts Day 3 to Day 16</time_frame>
    <description>Dehydroepiandrosterone sulphate (DHEA-S)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD androstenedione</measure>
    <time_frame>MAD Cohorts Day 3 to Day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD Fasting glucose</measure>
    <time_frame>MAD Cohorts Day 1 to Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD insulin</measure>
    <time_frame>MAD Cohorts Day 1 to Day 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD HOMA-IR</measure>
    <time_frame>MAD Cohorts Day 1 to Day 13</time_frame>
    <description>Homeostatic model assessment of insulin-resistance (HOMA-IR)</description>
  </secondary_outcome>
  <number_of_arms>20</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SAD Part 1 Placebo Cohort 1 Period 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Active Cohort Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Placebo Cohort 1 Period 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Active Cohort 1 Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Placebo Cohort 1 Period 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 1 Active Cohort 1 Period 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 2 Placebo Cohort 2 Period 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 2 Active Cohort 2 Period 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 2 Placebo Cohort 2 Period 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 2 Active Cohort 2 Period 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 2 Placebo Cohort 2 Period 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Part 2 Active Cohort 2 Period 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Placebo Cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Active Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Placebo Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Active Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Placebo Cohort 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Active Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Placebo Cohort 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD Active Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CORT125281, 40mg</intervention_name>
    <description>CORT125281 is supplied as capsules for oral dosing</description>
    <arm_group_label>SAD Part 1 Active Cohort Period 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone 25mg</intervention_name>
    <description>Challenge Agent, Dose and Route of Administration:
Standard release 25 mg tablets, orally administered</description>
    <arm_group_label>SAD Part 1 Placebo Cohort 1 Period 1</arm_group_label>
    <arm_group_label>SAD Part 1 Active Cohort Period 1</arm_group_label>
    <arm_group_label>SAD Part 1 Placebo Cohort 1 Period 2</arm_group_label>
    <arm_group_label>SAD Part 1 Active Cohort 1 Period 2</arm_group_label>
    <arm_group_label>SAD Part 1 Placebo Cohort 1 Period 3</arm_group_label>
    <arm_group_label>SAD Part 1 Active Cohort 1 Period 3</arm_group_label>
    <arm_group_label>SAD Part 2 Placebo Cohort 2 Period 4</arm_group_label>
    <arm_group_label>SAD Part 2 Active Cohort 2 Period 4</arm_group_label>
    <arm_group_label>SAD Part 2 Placebo Cohort 2 Period 5</arm_group_label>
    <arm_group_label>SAD Part 2 Active Cohort 2 Period 5</arm_group_label>
    <arm_group_label>SAD Part 2 Placebo Cohort 2 Period 6</arm_group_label>
    <arm_group_label>SAD Part 2 Active Cohort 2 Period 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Reference Therapy, Dose and Route of Administration:
Placebo capsule, orally administered</description>
    <arm_group_label>SAD Part 1 Placebo Cohort 1 Period 1</arm_group_label>
    <arm_group_label>SAD Part 1 Placebo Cohort 1 Period 2</arm_group_label>
    <arm_group_label>SAD Part 1 Placebo Cohort 1 Period 3</arm_group_label>
    <arm_group_label>SAD Part 2 Placebo Cohort 2 Period 4</arm_group_label>
    <arm_group_label>SAD Part 2 Placebo Cohort 2 Period 5</arm_group_label>
    <arm_group_label>SAD Part 2 Placebo Cohort 2 Period 6</arm_group_label>
    <arm_group_label>MAD Placebo Cohort 1</arm_group_label>
    <arm_group_label>MAD Placebo Cohort 2</arm_group_label>
    <arm_group_label>MAD Placebo Cohort 3</arm_group_label>
    <arm_group_label>MAD Placebo Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone 15mg Tablet</intervention_name>
    <description>Probe Substrate, Dose and Route of Administration:
15 Mg tablet, orally administered</description>
    <arm_group_label>MAD Placebo Cohort 1</arm_group_label>
    <arm_group_label>MAD Active Cohort 1</arm_group_label>
    <arm_group_label>MAD Placebo Cohort 2</arm_group_label>
    <arm_group_label>MAD Active Cohort 2</arm_group_label>
    <arm_group_label>MAD Placebo Cohort 3</arm_group_label>
    <arm_group_label>MAD Active Cohort 3</arm_group_label>
    <arm_group_label>MAD Placebo Cohort 4</arm_group_label>
    <arm_group_label>MAD Active Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CORT125281, dose to be determined</intervention_name>
    <description>CORT125281 is supplied as capsules for oral dosing</description>
    <arm_group_label>SAD Part 1 Active Cohort 1 Period 2</arm_group_label>
    <arm_group_label>SAD Part 1 Active Cohort 1 Period 3</arm_group_label>
    <arm_group_label>SAD Part 2 Active Cohort 2 Period 4</arm_group_label>
    <arm_group_label>SAD Part 2 Active Cohort 2 Period 5</arm_group_label>
    <arm_group_label>SAD Part 2 Active Cohort 2 Period 6</arm_group_label>
    <arm_group_label>MAD Active Cohort 1</arm_group_label>
    <arm_group_label>MAD Active Cohort 2</arm_group_label>
    <arm_group_label>MAD Active Cohort 3</arm_group_label>
    <arm_group_label>MAD Active Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Give written informed consent

          2. If male, have undergone vasectomy, with no wish to have the procedure reversed

          3. If female, using appropriate precautions to avoid pregnancy, defined as of
             nonchildbearing potential (ie, postmenopausal or permanently sterilised) or using
             highly effective contraception with low user-dependency

               -  A woman is postmenopausal if it is more than 12 months since her last
                  menstruation, without an alternative medical cause. A concentration of FSH in the
                  postmenopausal range may be used to confirm a postmenopausal state in women not
                  using hormonal contraception or hormonal replacement therapy.

               -  Accepted methods of permanent sterilization methods are hysterectomy, bilateral
                  salpingectomy and bilateral oophorectomy.

               -  An IUD is the only acceptable method of highly effective contraception with low
                  user-dependency, provided that the subject has tolerated its use for at least 3
                  months before the first dose of study medication and undertakes not to have it
                  removed for 1 month after the last dose.

          4. Be aged 18 to 65 years inclusive

          5. Have a BMI of 19 to 30 kg/m2, inclusive

          6. Be willing to comply with study restrictions as described in Section 4.6

          7. Be able to comply with the requirements of the entire study

          8. Be judged to be in good health, based upon the results of a medical history, physical
             examination, vital signs, 12-lead ECG, and clinical laboratory findings

          9. For multiple dose cohorts, have a morning serum cortisol within the local reference
             range at screening and/or Day −1

         10. Have suitable veins for multiple venepunctures/cannulation

         11. Be able to swallow size 0 capsules whole

        Exclusion Criteria:

          1. Be an employee or immediate family member of the CRU or Corcept

          2. Have been previously enrolled in this study

          3. Have multiple drug allergies, or be allergic to any of the components of study
             medication, its matching placebo, challenge agents or probe substrates (see Section
             5.1)

          4. Have a condition that could be aggravated by glucocorticoid blockade (eg, asthma, any
             chronic inflammatory condition) or activation (eg, immunodeficiency, active infection)
             Subjects with inactive seasonal hay fever may be included. Subjects with childhood
             (aged less than 18 years) asthma may be included provided they have had no symptoms
             and required no treatment for at least 5 years

          5. In the 6 calendar months before study drug administration, on average

               -  Have smoked more than 5 cigarettes/day

               -  Have consumed more than 14 units (female) or 21 units (male) of alcohol/week

               -  Consumed liquorice or other glycyrrhetic acid derivatives regularly, in the
                  judgement of the Investigator

          6. In the 3 calendar months before study drug administration

               -  Have donated blood or plasma in excess of 400 mL

               -  Have participated in another clinical trial of a new chemical entity or a
                  prescription medicine

          7. Have a positive test for alcohol, smoking or drugs of abuse at screening or admission
             to any of the dosing sessions

          8. Have clinically-relevant abnormal findings on vital signs, physical examination,
             laboratory screening tests, or 12-lead ECG, at screen and/or before first dose,
             including but not limited to:

               -  Abnormal ECG waveform morphology that would preclude accurate measurement of the
                  QT interval

               -  QTcF &gt;450 ms (from mean of 3 supine ECGs, performed at least 2 minutes apart)

               -  Stage 2 or higher hypertension (supine/semi-recumbent systolic blood pressure
                  [SBP] &gt;160 mmHg; diastolic blood pressure [DBP] &gt;100 mmHg, based on mean of
                  duplicate values recorded at least 2 minutes apart)

               -  Stage 1 hypertension (supine/semi-recumbent SBP 140-160 mmHg; DBP 90-100 mmHg,
                  based on mean of duplicate values recorded at least 2 minutes apart) associated
                  with indication for treatment ie, evidence of end-organ damage, diabetes or a 10
                  year cardiovascular risk, estimated using a standard calculator eg, QRisk2 2016
                  &gt;20%

               -  Glomerular filtration rate, estimated using the chronic kidney disease
                  epidemiology (collaboration) (CKD-EPI) method (eGFR; see Section 6.2.5) &lt;60
                  mL/minute/1.73 m2

               -  Hypokalaemia (potassium below lower limit of normal)

               -  ALT, AST and/or gammaglutamyl transferase (GGT) &gt;1.5 times the upper limit of
                  normal

               -  Seropositive for hepatitis B, hepatitis C or human immunodeficiency viruses.

          9. Have any medical or social reasons for not participating in the study raised by their
             General Practitioner/primary care physician

         10. Have any other condition that might increase the risk to the individual or decrease
             the chance of obtaining satisfactory data, as assessed by the Investigator

         11. Taken any prohibited prior medication, as described in Section 4.6.3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacie Shepherd, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Corcept Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Study Lead</last_name>
    <phone>650-327-3270</phone>
    <email>CorceptStudy600@corcept.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia M Fioretti</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucocorticoid receptor; antagonist</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cortisone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

